Randomized Clinical Trial on Hyperfractionated Versus Hypofractionated Preoperative Radiotherapy for Rectal Cancer: Long Term Outcomes Including Quality of Life Assessment

Wziętek, I.; Kryj, Mariusz; Idasiak, Adam; Chmielarz, Andrzej; Miszczyk, Leszek; Tukiendorf, Andrzej; Stobiecka, Ewa; Chmielik, Ewa; Wydmański, Jerzy; Namysł-Kaletka, A.; Gabryś, Dorota; Suwiński, Rafał

doi:10.1016/j.ijrobp.2014.05.114

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In order to verify the hypothesis that hyperfractionated accelerated radiotherapy (HART) may provide a favorable long-term outcome compared to hypofractionated RT, the pelvis was irradiated twice daily, with a minimal interfraction interval of 6h, and a total dose of 42 Gy was administered in doses of 1.5 Gy per fraction. 19 Surgery was performed 1–2 weeks after RT. The results showed that the physical, emotional, and social functioning of long-term survivors were significantly better with HART; however, when compared with hypofractionated RT, there was no significant difference regarding LC and OS.…”

Section: The Era Of 3d-crtmentioning

confidence: 99%

Dose–time fractionation schedules of preoperative radiotherapy and timing to surgery for rectal cancer

et al. 2020

View full text Add to dashboard Cite

Chemoradiotherapy (CRT) is extensively used prior to surgery for rectal cancer to provide significantly better local control, but the radiotherapy (RT), as the other component of CRT, has been subject to less interest than the drug component in recent years. With considerable developments in RT, the use of advanced techniques, such as intensity-modulated radiotherapy (IMRT) in rectal cancer, is garnering more attention nowadays. The radiation dose can be better conformed to the target volumes with possibilities for synchronous integrated boost without increased complications in normal tissue. Hopefully, both local recurrence and toxicities can be further reduced. Although those seem to be of interest, many issues remain unresolved. There is no international consensus regarding the radiation schedule for preoperative RT for rectal cancer. Moreover, an enormous disparity exists regarding the RT delivery. With the advent of IMRT, variations will likely increase. Moreover, time to surgery is also quite variable, as it depends upon the indication for RT/CRT in the clinical practices. In this review, we discuss the options and problems related to both the dose–time fractionation schedule and time to surgery; furthermore, it addresses the research questions that need answering in the future.

show abstract

Section: The Era Of 3d-crtmentioning

confidence: 99%

Dose–time fractionation schedules of preoperative radiotherapy and timing to surgery for rectal cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…All 53 patients completed the planned radiotherapy treatment. Because of bank holidays, radiotherapy was interrupted in three patients for a median of 3 days (range [1][2][3][4]. No interruptions resulted from toxicity.…”

Section: Toxicity Of Chemoradiationmentioning

confidence: 99%

“…The biological rationale 1 and clinical experience in locally advanced rectal cancer suggest that accelerated pre-operative hyperfractionated radiotherapy (HART) may provide a comparable local control but favourable tolerance compared with pre-operative treatment given in higher fraction doses. [2][3][4] Although the rate of locoregional recurrences after adequate pre-operative radiotherapy and surgery is relatively low, there is apparent need for further improvement in local control, particularly in high-risk patients. Also, in spite of implementation of new surgical and radiotherapy strategies, the rate of distant metastases remains high.…”

Section: Introductionmentioning

confidence: 99%

Pre-operative hyperfractionated concurrent radiochemotherapy for locally advanced rectal cancers: a phase II clinical study

Idasiak

Galwas-Kliber

Behrendt

et al. 2017

BJR

View full text Add to dashboard Cite

The proposed pre-operative HART with co-administration of 5FU had acceptable toxicity profile and provided satisfactory rate of ypCR. This created rationale to initiate a Phase III randomized study that was registered under ClinicalTrials.gov Identifier: NCT01814969. Advances in knowledge: The results of this research show that responders to pre-operative radiochemotherapy have favourable outcome. Tumour regression grade as prognostic clinical feature holds the promise of better classifying patients at high risk of local and systemic recurrence and this issue may be an interesting objective for future research.

show abstract

“…Drugie prezentowane randomizowane badanie kliniczne III fazy jest autorstwa polskich badaczy z Instytutu Onkologii w Gliwicach pod kierownictwem dr Iwony Wziętek [5]. Porównali oni dwa schematy radioterapii przedoperacyjnej: hypo-i hyperfrakcjonowany (HYPO i HART).…”

unclassified

Ocena najnowszych trendów w diagnozowaniu, leczeniu nowotworów złośliwych w lokalizacji dolnego odcinka przewodu pokarmowego na podstawie konferencji ASTRO’s 56th Annual Meeting

Janiga¹

2016

LOS

View full text Add to dashboard Cite

Na konferencji ASTRO 56th Meeting w części poświęconej nowotworom dolnego odcinka przewodu pokarmowego prezentowane były najnowsze doniesienia dotyczące raka odbytnicy i odbytu. Praktycznie brak nowych badań ściśle związanych z rakiem okrężnicy, zarówno w wystąpieniach ustnych jak i plakatowych.Standardy leczenia raka odbytnicy nie uległy zmianie, jednak zarysowują się trendy: deeskalacja leczenia chirurgicznego oraz propozycje modyfikacji – skracania czasu trwania leczenia neoadjuwantowego.

show abstract

Randomized Clinical Trial on Hyperfractionated Versus Hypofractionated Preoperative Radiotherapy for Rectal Cancer: Long Term Outcomes Including Quality of Life Assessment

Cited by 4 publications

References 0 publications

Dose–time fractionation schedules of preoperative radiotherapy and timing to surgery for rectal cancer

Dose–time fractionation schedules of preoperative radiotherapy and timing to surgery for rectal cancer

Pre-operative hyperfractionated concurrent radiochemotherapy for locally advanced rectal cancers: a phase II clinical study

Ocena najnowszych trendów w diagnozowaniu, leczeniu nowotworów złośliwych w lokalizacji dolnego odcinka przewodu pokarmowego na podstawie konferencji ASTRO’s 56th Annual Meeting

Contact Info

Product

Resources

About